11 citations
,
January 2021 in “Breast Care” This study found that quality of life, overall survival, and progression-free survival are the most important factors for postmenopausal patients with advanced breast cancer when considering treatment options.
January 2023 in “Figshare” This study reported that postmenopausal patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival over therapy-related side effects when considering cancer treatment decisions.
January 2023 in “Figshare” This study found that for postmenopausal patients with advanced breast cancer, quality of life, overall survival, and progression-free survival are the most important factors in treatment decisions, while side effects hold less importance.
July 2026 in “Journal of the American Academy of Dermatology” Baricitinib helps regrow hair in severe alopecia areata, with results varying by initial hair loss severity and episode duration.
June 2022 in “C&EN global enterprise” This source notes that Olumiant (baricitinib), a rheumatoid arthritis drug by Eli Lilly and Company, has been approved as the first systemic treatment for severe alopecia areata.